MarginsXMarginsX
Home › Markets › Health Care › NUWE

Nuwellis Inc. (NUWE)

NUWE trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.48
-8.57% on the day
Market cap
$2.4M
Nano cap
Revenue · 2025
$8.3M
-5.4% on 2024
Net income · 2025
-$17.5M
-211.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1506492/000114036126009080/0001140361-26-009080-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNUWE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001506492
SEC industry codeElectromedical & Electrotherapeutic Apparatus
Incorporated inDE

Financials · 2025

LineValue
Revenue$8.3M
Net income-$17.5M
Operating income-$11.1M
Net margin-211.9%
Operating margin-134.3%
Revenue growth-5.4%
Cash$1.1M
Total assets$6.1M
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
8.1 months
$8.3M cash at September 30, 2026
Share count, 1 year
+10171.7%
2025-11-07 to 2026-11-10 · +7674398.3% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"While the Company is confident in its ability to fund operations and execute on its strategic plan, there can be no assurance that additional capital will be available on favorable terms, or at all, or that the Company will achieve profitability. 7 Table of Contents These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $ 327.7 million, and the need for "
10-Q 2026-11-12
Cash and burn$8.3M cash; operating cash flow -$3.1M a quarter.Report 2026-09-30
Shares outstanding540,912 (2026-11-10); 1,658,799 a year earlier; 3,263,657 three years earlier. 1y figure adjusted for splits (1-for-315 overall); 3y figure adjusted for splits (1-for-463050 overall).Cover page 2026-11-10
Reverse splits, 3 years4; latest 1-for-9 on 2026-10-27Source 2026-10-27
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, Minneapolis, Minnesota, United StatesPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.2M-$2.0M-$3.0M$8.3MNo debt tags$9.0M10-Q 2026-11-12
Q2 2026
2026-06-30
$2.0M-$4.8M-$3.2M$3.9MNo debt tags$9.0M10-Q 2026-08-13
Q1 2026
2026-03-31
$2.4M-$4.5M-$3.1M$2.1MNo debt tags$8.8M10-Q 2026-05-15
Q4 2025
2025-12-31
$2.4M-$2.4M-$3.0M$1.1MNo debt tags$8.3M10-K 2026-03-11
Q3 2025
2025-09-30
$2.2M$468K-$3.1M$3.1MNo debt tags$8.2M10-Q 2026-11-12
Q2 2025
2025-06-30
$1.7M-$12.6M-$2.1M$4.5MNo debt tags$8.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$1.9M-$3.0M-$2.5M$2.6MNo debt tags$8.8M10-Q 2026-05-15
Q4 2024
2024-12-31
$2.3M-$1.5M-$1.5M$5.1MNo debt tags$8.7M10-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-08-26
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxy
FORM DEF 14A
DEF 14A2026-07-07

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.0%
1 month+690.3%
3 months+276.9%
Year to date-92.0%
1 year-94.3%
From 52-week high-96.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus

TickerCompanyPriceDayMarket cap
NXLNexalin Technology Inc.$1.56+2.30%$1.9M
VBIOValion Bio Inc.$0.5290+0.84%$1.1M
NDRAENDRA Life Sciences Inc.$4.42-1.78%$6.6M
IRIXIRIDEX Corporation$0.6878-0.32%$12.1M
ITOCiTonic Holdings Ltd$1.88-5.05%$13.8M
QTIQT Imaging Holdings Inc.$1.80-4.26%$26.4M
ECORelectroCore Inc.$4.84-7.81%$44.7M
POCIPrecision Optics Corporation Inc.$4.97-4.97%$54.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier